Laser Microdissection and Proteomic Analysis of Amyloidosis, Cryoglobulinemic GN, Fibrillary GN, and Immunotactoid Glomerulopathy

Sanjeev Sethi,* Jason D. Theis,* Julie A. Vrana,* Fernando C. Fervenza,† Anjali Sethi,‡ Qi Qian,§ Patrick Quint,* Nelson Leung,* Ahmet Dogan,* and Samih H. Nasr*

Summary

Background and objectives Organized deposits are present in amyloidosis, fibrillary GN, and immunotactoid glomerulopathy. However, the constituents of the deposits are not known.

Design, setting, participants, & measurements Laser microdissection of glomeruli followed by mass spectrometry was performed to determine the composition of the deposits. The results were compared with cryoglobulinemic GN.

Results The results are divided into four major groups: amyloidogenic proteins, structural/other proteins, complement proteins, and Igs. With regards to amyloidogenic proteins, large spectra numbers of apolipoprotein E are noted in amyloidosis (41.8±20.9) compared with fibrillary (15.6±12.5) and immunotactoid (12.3±12) glomerulopathy. Apolipoprotein E was absent in cryoglobulinemic GN. Serum amyloid P component is present in deposits in amyloidosis, whereas it is absent in fibrillary and cryoglobulinemic GN. However, large spectra numbers of Ig γ-1 chain C region are present in immunotactoid glomerulopathy (47.3±34.6) compared with fibrillary (16.25±19.7) and cryoglobulinemic (13.3±4.9) GN. All cases of Ig light chain-associated amyloidosis showed spectra for the respective Ig light-chain C region (mean=10±1.7).

Conclusions Based on the spectra numbers, the study shows that the relative amount of apolipoprotein E to Ig light-chain C region/amyloidogenic proteins or Ig γ-1 chain C region is associated with the organization of the deposits in amyloidosis, fibrillary GN, and immunotactoid glomerulopathy. However, the absence of apolipoprotein E correlates with the lack of fibrillar deposits in cryoglobulinemic GN.

Introduction

The most common renal diseases with organized deposits are amyloidosis, fibrillary GN, and immunotactoid glomerulopathy. The conditions often present with nephrotic syndrome. Amyloid deposits are Congo red-positive, whereas the deposits in fibrillary GN and immunotactoid glomerulopathy are Congo red-negative. Most cases of amyloidosis are Ig light chain-associated (AL), although many forms of amyloidosis are nonlight chain (or less commonly, heavy chain) associated, such as amyloidosis associated with serum amyloid A protein, leukocyte cell-derived chemotaxon-2 (LECT2), and fibrinogen α-chain. Amyloid fibrils are randomly arranged and measure 8–12 nm in diameter, whereas the fibrils in fibrillary GN are also randomly arranged and measure 10–30 nm in diameter. The microtubules in immunotactoid glomerulopathy are often arranged in parallel arrays and measure 10–90 nm in diameter (1,2). Electron microscopy is often needed to make the definitive diagnosis. Most investigators favor separating fibrillary GN from immunotactoid glomerulopathy, whereas others combine fibrillary GN with immunotactoid glomerulopathy into a single group (3–8). Patients with immunotactoid glomerulopathy are more likely to have low complement titers, dysproteinemia, hematologic malignancy, and monoclonal glomerular deposits compared with patients with fibrillary GN, but significant overlap exists between the two pathologic entities (3,4,6,7). The pathogenesis of the fibrillary and microtubular deposits in amyloidosis, fibrillary GN, and immunotactoid glomerulopathy is not understood.

We performed laser microdissection (LMD) of the glomeruli followed by tandem mass spectrometry (MS) -based proteomics analysis to better understand the composition of the deposits and what might lead to the organization of the deposits in these conditions (9). The proteomic analysis of renal amyloidosis was recently described in detail by our group (9,10). In this study, we compare the glomerular protein profile of amyloidosis with the profile cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy.

*Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology and †Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; and ‡Drexel University College of Medicine, Philadelphia, PA

Correspondence: Dr. Sanjeev Sethi, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905. Email: sethi.sanjeev@mayo.edu

Materials and Methods
Case Selection
A retrospective review of renal biopsies from seven cases of renal amyloidosis, eight cases of fibrillary GN, four cases of immunotactoid glomerulopathy, and four cases of cryoglobulinemic GN was performed. The biopsy material was sent to the Mayo Clinic Renal Pathology Laboratory for diagnosis and interpretation over a 5-year period (2007–2012). In all cases, routine evaluation, including light microscopy, immunofluorescence microscopy, and electron microscopy, was reviewed. For normal controls, we used day 0 protocol biopsy material from kidney transplant recipients. Clinical information was obtained from the charts. The Institutional Review Board at the Mayo Clinic approved the study.

Specimen, Specimen Preparation, LMD, and MS-Based Proteomic Analysis
The methods have previously been published (9–11). The licensed patent rights to perform protein extraction from paraffin-embedded tissue for the MS-based amyloid testing have been granted by OncoPlex Diagnostics (formerly Expression Pathology Inc.). Briefly, for each case, glomeruli were identified in 6-μm-thick sections of formalin-fixed paraffin-embedded tissues under bright field light. Glomeruli were identified using hematoxylin and eosin-stained sections for nonamyloidosis cases and Congo red-stained sections for amyloidosis. The glomeruli are laser microdissected using the Leica dissector (Leica DM 600). Stained sections for nonamyloidosis cases and Congo stained sections were reviewed. For normal controls, we used day 0 protocol biopsy material from kidney transplant recipients. Clinical information was obtained from the charts. The Institutional Review Board at the Mayo Clinic approved the study.

Identification and quantitation of peptides were performed using the ProteinChip Array Protein Identification System. Peptide identification will be deemed clinically valid. However, the semiquantitative nature of the technique and high variability preclude statistical comparisons. Results are presented as mean ± SD.

Results
Clinical and Pathologic Findings
The clinical characteristics at the time of presentation are shown in Table 1.

Amyloidosis. We selected seven representative cases of amyloidosis for LMD and MS (cases 1–7). These cases included two cases of serum amyloid A protein/reactive secondary amyloidosis (AA; cases 1 and 2), three cases of AL amyloidosis (cases 3–5), and two cases of LECT2 amyloidosis (cases 6 and 7). Of three AL amyloidosis cases, two cases were AL λ-light chain type (cases 3 and 4), and one case was AL κ-light chain type (case 5).

Cryoglobulinemic GN. We selected four representative cases of cryoglobulinemic GN (cases 8–11). Electron microscopy studies did not show tubular substructure in any of the cases. Three patients had hepatitis C (cases 8, 9, and 11), whereas one patient had rheumatoid arthritis and vasculitis (case 10). All cases showed positive serology for cryoglobulins.

Fibrillary GN. We selected eight representative cases of fibrillary GN (cases 12–19). All cases showed glomerular fibrillary deposits that were Congo red-negative. All eight cases showed glomerular mesangial and capillary wall staining for IgG (2–3+), C3 (1–2+), κ-light chains (1–3+), and/or λ-light chains (trace to 2+) on immunofluorescence microscopy. One case also showed small amounts of mesangial IgA (1+; case 8). Five cases were evaluated for paraproteinemia, of which four cases were negative and one case showed a monoclonal IgG κ-paraprotein (case 12).

Immunotactoid Glomerulopathy. We selected four representative cases of immunotactoid glomerulopathy (cases 20–23). All cases showed glomerular deposits with a microtubular substructure. Immunofluorescence studies in case 20 showed IgG (2+), IgM (1–2+), C3 (2+), and λ-light chains (2+), with trace staining for κ-light chains. Case 21 showed IgG and λ-light chains (with negative κ-light chains). Case 22 showed IgG (3+) and κ-light chains (1+; with negative λ-light chains), whereas case 23 showed IgA (1–2+), IgG (2+), IgM (2+), C3 (2+), κ-light chains (2+), and λ-light chains (1+). Case 20 had multiple myeloma with IgG-κ on electrophoresis studies, case 22 had chronic lymphocytic leukemia with IgG-κ on electrophoresis studies; and case 23 did not have any hematologic malignancy but did have IgA-κ on electrophoresis studies; in case 21, hematologic evaluation was not available. All cases were negative for cryoglobulins, and serological evaluation for autoimmune diseases was negative.

Normal. We used two cases (cases 24 and 25) of day 0 protocol biopsies of kidney transplant as normal controls. Light microscopy showed normal-appearing glomeruli in both cases.

Representative electron microscopy findings from cases of amyloidosis, cryoglobulinemic GN (case 11), fibrillary GN (case 13), and immunotactoid glomerulopathy (case 22) are shown in Figure 1.
Table 1. Clinical characteristics of patients

<table>
<thead>
<tr>
<th>Case Number</th>
<th>Disease</th>
<th>Age (yr)/Sex</th>
<th>Serum Creatinine (mg/dl)</th>
<th>24-h Urine Protein (g/d)</th>
<th>Hematuria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AA</td>
<td>66/woman</td>
<td>3.2</td>
<td>9.2</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>AL</td>
<td>63/man</td>
<td>NA</td>
<td>NA</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>AL</td>
<td>55/woman</td>
<td>9.7</td>
<td>Nephrotic range</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>AL</td>
<td>64/woman</td>
<td>NA</td>
<td>Nephrotic range</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>ALECT2</td>
<td>69/man</td>
<td>1.4</td>
<td>12.6</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>Cryoglobulinemic GN</td>
<td>72/man</td>
<td>1.5</td>
<td>6.1</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>Cryoglobulinemic GN</td>
<td>70/woman</td>
<td>1.8</td>
<td>0.7</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>Cryoglobulinemic GN</td>
<td>51/man</td>
<td>2.4</td>
<td>1.4</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>Cryoglobulinemic GN</td>
<td>59/man</td>
<td>3.5</td>
<td>&gt;300 mg/dl on UA</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>Fibrillary GN</td>
<td>37/man</td>
<td>0.9</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td>11</td>
<td>Fibrillary GN</td>
<td>63/woman</td>
<td>1.4</td>
<td>NA</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>Fibrillary GN</td>
<td>68/man</td>
<td>0.8</td>
<td>5.2</td>
<td>Yes</td>
</tr>
<tr>
<td>13</td>
<td>Fibrillary GN</td>
<td>64/man</td>
<td>1.2</td>
<td>1.7</td>
<td>Yes</td>
</tr>
<tr>
<td>14</td>
<td>Fibrillary GN</td>
<td>26/woman</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>15</td>
<td>Fibrillary GN</td>
<td>66/man</td>
<td>1.0</td>
<td>3.7</td>
<td>Yes</td>
</tr>
<tr>
<td>16</td>
<td>Fibrillary GN</td>
<td>50/woman</td>
<td>0.9</td>
<td>0.7</td>
<td>Yes</td>
</tr>
<tr>
<td>17</td>
<td>Fibrillary GN</td>
<td>66/woman</td>
<td>1.6</td>
<td>8</td>
<td>Yes</td>
</tr>
<tr>
<td>18</td>
<td>Immunotactoid GN</td>
<td>56/man</td>
<td>1.2</td>
<td>13.4</td>
<td>No</td>
</tr>
<tr>
<td>19</td>
<td>Immunotactoid GN</td>
<td>26/woman</td>
<td>2.7</td>
<td>6.4</td>
<td>Yes</td>
</tr>
<tr>
<td>20</td>
<td>Immunotactoid GN</td>
<td>52/woman</td>
<td>3.2</td>
<td>7</td>
<td>Yes</td>
</tr>
<tr>
<td>21</td>
<td>Immunotactoid GN</td>
<td>56/woman</td>
<td>4</td>
<td>12</td>
<td>NA</td>
</tr>
</tbody>
</table>

AA, serum amyloid A protein/reactive secondary amyloidosis; AL, Ig light-chain amyloidosis; NA, not available; ALECT2, leukocyte cell-derived chemotaxin-2 amyloidosis; UA, urinalysis.

MS

We divide the results into four major groups: amyloidogenic proteins, structural proteins, complement proteins, and Ig proteins.

**Amyloidogenic Proteins.** Apolipoprotein E is a major constituent of amyloid (9) (Figure 2A). Apolipoprotein E was also present in fibrillary GN and immunotactoid glomerulopathy, but the spectra numbers were smaller in comparison, whereas glomeruli of cryoglobulinemic GN did not contain apolipoprotein E (Figure 3). Thus, we find that glomeruli from amyloidosis contain larger spectra numbers of apolipoprotein E (mean=41.8±20.9, range=10–71, median=36) compared with glomeruli from fibrillary GN and immunotactoid glomerulopathy (mean=15.6±12.5, range=2–38, median=11 for fibrillary GN; mean=12.3±12, range=2–29, median=9 for immunotactoid glomerulopathy). Glomeruli from amyloidosis contain large spectra numbers for serum amyloid P component (SAP; mean=14.1±6.7, range=5–24, median=11). Surprisingly, small spectra numbers of SAP were present in immunotactoid glomerulopathy (mean=4.8±3, range=2–9, median=4), whereas SAP was negative in cryoglobulinemic and fibrillary GN (Figure 3). As expected, large spectra numbers of serum AA protein and LECT2 were present exclusively in AA and LECT2 amyloidosis, respectively.

**Structural/Other Proteins.** Important differences were noted in spectra numbers of vitronectin, basement membrane-specific heparan sulfate, fibronectin, clusterin, vinculin, collagen chains, and fibrillin between amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy (Figure 2B).

Glomeruli from amyloidosis contain large spectra numbers of vitronectin (mean=39.1±21.7, range=19–77, median=32) compared with glomeruli from fibrillary GN (mean=13.1±11.0, range=2–36, median=14.5) and immunotactoid glomerulopathy (mean=13.5±11.6, range=9–27, median=18). Glomeruli from cryoglobulinemic GN did not contain significant spectra numbers of vitronectin.

Large spectra numbers of basement membrane heparan sulfate and fibronectin are noted in cryoglobulinemic GN (mean=22.8±22, range=6–55, median=15 and mean=30.8±14.3, range=18–50, median=27.5, respectively) and immunotactoid GN (mean=34.5±18.7, range=15–58, median=32.5 and mean=26.3±21.7, range=8–55, median=21, respectively) compared with fibrillary GN (mean=9.8±12.3, range=2–34, median=10 and mean=6.6±8.2, range=6–14, median=9.5). Vinculin is also present in cryoglobulinemic GN (mean=8±6.3, range=2–16, median=7), fibrillary GN (mean=3.8±4.4, range=2–11, median=4), and immunotactoid glomerulopathy (mean=11±3.1, range=8–15, median=10.5). Glomeruli from amyloidosis did not contain basement membrane heparan sulfate, fibronectin, or vinculin.

Clusterin is present in amyloidosis (mean=10.7±9.0, range=5–24, median=10), fibrillary GN (mean=6.6±4.4, range=3–14, median=7), and immunotactoid glomerulopathy (mean=11±3.1, range=4–15, median=9), whereas it is absent in cryoglobulinemic GN. Fibrillin was noted in three of four cases of immunotactoid glomerulopathy, two of four cases of cryoglobulinemic GN, and one case of light- and heavy-chain amyloidosis (case 5), whereas it was absent in fibrillary GN.
Collagen α-2(I) chain is present in amyloidosis (mean=8.8 ± 5.0, range=6–16, median=10), whereas it was absent in cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy (except one case that showed low spectra numbers).

Complement Proteins. Large spectra numbers of C3 are noted in fibrillary (mean=28.4 ± 15.8, range=12–50, median=32), immunotactoid glomerulopathy (mean=30.2 ± 22.4, range=8–52, median=37.5), and cryoglobulinemic GN (mean=9.3 ± 3.4, range=6–14, median=7) (Figure 2C). C4 and C9 are also detected in fibrillary GN (C4: mean=16±10.9, range=5–30, median=17) and immunotactoid glomerulopathy (C4: mean=5.8±1.9, range=3–7, median=5), indicating activation of the classic and terminal pathway of complement.

Glomeruli involved by amyloidosis showed small spectra numbers of C3 and C9 in one of four cases of AL amyloidosis. This case also contained large spectra for Ig γ-1 chain C region, indicating a heavy-chain component. Both cases of AA amyloidosis contained spectra for C3 and C4, and one of two cases of LECT2 amyloidosis also contained C3 and C4.

Ig/Amyloidogenic Proteins. Large spectra numbers for Ig γ-1 chain C region are present in glomeruli from cryoglobulinemic GN (mean=13.3 ± 4.9, range=6–17, median=15), fibrillary GN (mean=16.3 ± 19.7, range=4–64,
(mean=47.3 ± 34.6, range=13–78, median=49) (Figure 2D). Spectra numbers were highest in immunotactoid glomerulopathy (Figure 3). One case (case 5) of AL amyloidosis also contained significant spectra numbers for Ig \text{g}-1 chain C region that likely represented a heavy-chain component. Small spectra numbers were also noted in one case of AA amyloidosis that likely represented entrapped plasma proteins. All three cases of AL showed specific spectra for the respective light chains (mean=10 ± 6, range=7–12, median=9): A-light chains in cases 3 and 4 and k-light chains in case 5. Two cases of immunotactoid glomerulopathy (cases 20 and 21) showed large spectra numbers for Ig \text{g}-1 C region, and two cases (cases 22 and 23) showed large spectra numbers for Ig \text{k}-1 C region. Glomeruli from cryoglobulinemic GN contained large spectra for Ig \text{k}-\text{C} region in addition to Ig \text{g}-1 chain C region.

**Normal.** Glomeruli from normal glomeruli showed large spectra for actin, vimentin, actinin, and hemoglobin and smaller spectra for albumin, histones, etc.

**Discussion**

We compare the glomerular proteomics of amyloidosis, cryoglobulinemic GN, fibrillary GN, immunotactoid glomerulopathy, and normal (control) glomeruli. The probability number (>95% is highlighted by green; 8%–94% by yellow) indicates essentially the percent homology between peptides detected in the specimens and the published amino acid sequences of their corresponding proteins. AA, amyloid A protein/reactive secondary amyloidosis; AL, Ig light-chain amyloidosis; ALECT2, amyloidosis associated with leukocyte cell-derived chemotaxin-2.

**Figure 2.** Mass spectrometry results. Scaffold 2 display of proteomic data showing the (A) amyloidogenic proteins, (B) structural proteins, (C) complement proteins, and (D) Igs in amyloidosis, cryoglobulinemic GN, fibrillary GN, immunotactoid glomerulopathy, and normal (control) glomeruli. The probability number (>95% is highlighted by green; 8%–94% by yellow) indicates essentially the percent homology between peptides detected in the specimens and the published amino acid sequences of their corresponding proteins. AA, amyloid A protein/reactive secondary amyloidosis; AL, Ig light-chain amyloidosis; ALECT2, amyloidosis associated with leukocyte cell-derived chemotaxin-2.
MS. We divide the findings into four groups of proteins: amyloidogenic proteins, structural/other proteins, complement factors, and Ig.

We find that the basic amyloidogenic protein apolipoprotein E is present in all organized deposits, with relatively large spectra numbers in amyloidosis and in comparison, lower spectra numbers in fibrillary GN and immunotactoid glomerulopathy (amyloidosis > fibrillary GN > immunotactoid glomerulopathy). It is absent in non-organized deposits of cryoglobulinemic GN. Large spectra numbers of SAP are always noted in amyloidosis. However, SAP is not present or present in very low spectra numbers in fibrillary GN and immunotactoid glomerulopathy, indicating that SAP is not required for fibrillar or microtubular substructure.

Glomeruli from cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy contain large spectra numbers for Ig γ-1 chain C region. However, spectra numbers are highest in immunotactoid glomerulopathy followed by fibrillary GN and cryoglobulinemic GN.

Taken together, these findings suggest that Ig light- or heavy-chain C region along with apolipoprotein E is key to organization of the deposits: high spectra numbers of Ig γ-1 chain region and low spectra numbers of apolipoprotein E are found in immunotactoid glomerulopathy, mid-level spectra numbers of Ig γ-1 chain region and mid levels of apolipoprotein E are found in fibrillary glomerulopathy, whereas Ig light-chain region and high spectra numbers of apolipoprotein E are found in amyloidosis (Figure 3).

We also noted differences in the spectra numbers of structural proteins between the four conditions. Vitronectin mirrors the spectra numbers of apolipoprotein E, with high spectra numbers in amyloidosis and lower spectra numbers in fibrillary GN and immunotactoid glomerulopathy. In general, other than vitronectin and clusterin, we noted higher spectra numbers of structural proteins, such as basement membrane heparan sulfate and fibronectin, in cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy compared with amyloidosis. However, collagen α-2(I) chain is present in amyloidosis, whereas it is absent in cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy (except in low numbers in one case). The significance of these findings is not clearly understood at this time, although the proteins likely contribute to the organization of the deposits.

With regards to complement proteins, we find proteins of the classic and terminal pathways in both fibrillary GN and immunotactoid glomerulopathy. We detected high spectra numbers of C3 in all cases, C4 in 11 of 12 cases, and C9 in 9 of 12 cases of fibrillary GN and immunotactoid glomerulopathy. Surprisingly, we noted C3 in all cases of cryoglobulinemic GN but failed to detect components of the terminal pathway. Complement proteins were absent in AL amyloidosis, except one case that had a heavy-chain component.
Limitations of the study include the relatively small sample size as well as the recognition that the spectra number is not absolutely quantitative, although a higher spectra number is indicative of greater abundance of the protein. Another limitation of the study is that not all proteins digest into the proper size fragments with trypsin and the peptides do not all ionize similarly.

In conclusion, our studies compare the proteomic profile of the deposits in amyloidosis with the profiles of cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Based on the spectra numbers, we find that the relative amount of apolipoprotein E compared with Ig heavy- and/or light-chain C regions determines the type of deposits present in amyloidosis, fibrillary GN, and immunotactoid glomerulopathy. It is tempting to speculate that future therapy could target proteins such as apolipoprotein E and interfere with the formation and tissue deposition of organized deposits.

Disclosures
None.

References

Received: July 12, 2012 Accepted: January 16, 2013

Published online ahead of print. Publication date available at www.cjasn.org.